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Background.  Currently, no data are available on the burden of morbidity and mortality in people with HIV-1 (PWH) harboring a 
4-class drug-resistant (4DR) virus (nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease 
inhibitors, integrase strand transfer inhibitors). The study aimed to assess the incidence of clinical events and death in this population.
Methods.  This was a cohort study on PWH from the PRESTIGIO Registry with a documented 4DR virus. Burden of disease was 
defined as the occurrence of any new event including an AIDS-defining event (ADE) or non-AIDS-defining event (NADE) or death from 
any cause after 4DR evidence (baseline). Cox regression models evaluated factors associated with the risk of new clinical events/death.
Results.  Among 148 PWH followed for a median (interquartile range) of 47 (32–84) months after 4DR evidence, 38 PWH had 
62 new events or died from any cause (incidence rate, 9.12/100 person-years of follow-up; 95% CI = 6.85–11.39): 12 deaths (6 AIDS-
related and 6 non-AIDS-related), 18 ADEs, 32 NADEs; 20 of the 38 NADEs (45%) of the incident clinical events were malignancies. 
The 4-year cumulative incidence of death was 6% (95% CI, 3%–13%), and that of ≥1 event or death was 22% (95% CI, 16%–31%). 
A higher risk of new clinical events/death was more likely in PWH with previous clinical events (adjusted hazard ratio [aHR], 2.67; 
95% CI, 1.07–6.67) and marginally associated with lower baseline CD4+/CD8+ ratio (aHR, 0.82; 95% CI, 0.65–1.02).
Conclusions.  PWH harboring 4DR have a high burden of disease with a worrying incidence of malignancies, strongly ad-
vising for close prevention and monitoring interventions as well as access to innovative therapeutic strategies, especially in people 
with a history of clinical events and low CD4+/CD8+ ratio.
Keywords.  AIDS-defining event; cancer; death; 4-class drug resistance; non-AIDS-defining event.
Since 2007, antiretroviral therapy (ART) regimens based on 
an integrase strand transfer inhibitor (INSTI) have been intro-
duced and largely used both in treatment-naïve and treatment-
experienced people because of their safety and efficacy, as 
demonstrated in many clinical trials and observational studies 
[1, 2]. The widespread use of INSTI-based regimens, particu-
larly first-generation agents, has led to the emergence of INSTI 
resistance in a limited proportion of people with HIV-1 in-
fection (PWH) [3]. Italian data reported a 9% prevalence of 
multiclass drug resistance (MDR; defined as a virus with at least 
1 major resistance mutation in at least 3 different drug classes 
[nucleoside reverse transcriptase inhibitors [NRTIs], non-
nucleoside reverse transcriptase inhibitors [NNRTIs], protease 
inhibitors [PIs], INSTIs]) in ART-experienced HIV-1 infected 
people in the period 2011–2018 [4]. The prevalence of 4-class 
drug resistance (4DR; ie, with NRTI, NNRTI, PI, INSTI resist-
ance) has recently risen from 1% in 2008–2013 to 3% and 2% in 
2014–2016 and 2017–2018, respectively [4].
Previous studies have suggested that people with 3-class drug 
resistance have a particularly poor prognosis, with high mor-
bidity and mortality. An Italian cohort study [5] including 623 
people with HIV and triple-class virological failure (TCVF), 
followed in 1999–2002 for a median follow-up (interquartile 
range [IQR]) of 21 (7–37) months, reported an incidence rate 
(IR) of death from any cause equal to 11.9/100 person-years of 
follow-up (PYFU) and an IR of AIDS-related death of 9.4/100 
PYFU. In addition, the 48-month probability of new AIDS 
events/death was estimated to be 35.9%.
In a previous European multicohort study [6] including PWH 
with TCVF, the estimated incidence rate of AIDS-defining 
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events (1.2/100 PYFU in 2009) and the mortality rate (1.4/100 
PYFU in 2008)  did not decrease significantly in 9  years of 
follow-up.
To date, however, data on the burden of AIDS-related and 
non-AIDS-related morbidity in PWH harboring a 4DR virus 
are not available. Using the PRESTIGIO Registry, the aim of this 
analysis was to evaluate the incidence of AIDS-related and non-
AIDS-related events and death in this population.
METHODS
The PRESTIGIO Registry (www.registroprestigio.com) is an 
observational, prospective, Italian, multicenter, annual collec-
tion of data on clinical, laboratory, treatment, and virological 
characteristics of PWH and 4DR viruses.
The registry includes people with the following character-
istics: age >14 years; documented resistance to the 4 classes 
of antiretroviral drugs (NRTIs, NNRTIs, PIs, INSTIs), de-
fined as intermediate or high-level resistance to at least 1 
drug of each class according to the Stanford algorithm; if no 
INSTI genotypic resistance test is available, a documented 
virological failure to an INSTI-regimen was accepted as an 
inclusion criterion. The PRESTIGIO Registry is registered on 
the ClinicalTrials.gov website with the following identifier: 
NCT04098315.
In this analysis, we included people from the PRESTIGIO 
Registry with an available and verified clinical history and with 
≥1 clinical visit after the date of the first evidence of a 4DR virus 
(baseline).
The outcomes for the present analysis were the incidence 
of (i) ≥1 new AIDS event or non-AIDS event or death from 
any cause; (ii) death from any cause; (iii) ≥1 new AIDS event 
or AIDS-related death; (iv) ≥1 new non-AIDS event or 
non-AIDS-related death.
AIDS events were defined according to the Centers for 
Disease Control and Prevention’s 1993 Revised Classification 
System for HIV Infection and Expanded Surveillance Case 
Definition for AIDS Among Adolescents and Adults [7].
Non-AIDS events included non-AIDS-related malignancies, 
major adverse cardiovascular events (MACEs), decompen-
sated cirrhosis, chronic kidney disease (CKD), and diabetes. 
MACEs included acute myocardial infarction, coronary dis-
ease requiring invasive procedures, congestive heart failure, and 
stroke. CKD was defined as the occurrence of 2 consecutive (at 
least 3 months apart) estimated glomerular filtrate rate deter-
minations <60 mL/min/1.73 m2 (using the CKD Epidemiology 
Collaboration Equation formula).
All incident clinical events that occurred from baseline to 
March 2019 (administrative censoring date) were considered in 
the analyses. Patients might have experienced a clinical event 
(AIDS-related or non-AIDS-related) before baseline.
Patient Consent Statement
The protocol of the PRESTIGIO Registry was approved (pro-
tocol number 41/int/December 2017)  by the San Raffaele 
Ethical Committee (coordinating center) in December 2017. 
Forty Infectious Diseases clinical centers, located in almost all 
the Italian regions, are actively participating, and their ethics 
committees approved the registry protocol; all patients pro-
vided written informed consent to be enrolled.
Statistical Analysis
Results are described as median (interquartile range) and 
frequency (%).
Distributions of laboratory parameters were compared be-
tween PWH with vs without events using the Wilcoxon rank-
sum test for continuous variables and the chi-square/Fisher 
exact test for categorical variables; we considered the nearest 
values to the date of the first event (within 90 days before the 
event) for people with events and the last available value for 
people without events. Incidence rates (IRs) were estimated 
by univariate Poisson regression as number of events recorded 
after baseline and PYFU and expressed as rate per 100 PYFU, 
with 95% confidence intervals. As participants could experience 
>1 incident event, in measuring incidence the occurrence of 
different types of clinical events was allowed, while recurrences 
of the same type of event were excluded. In these analyses, fol-
low-up started at BL and ended at the date of the incident clin-
ical events, date of death, or date of the last available visit.
For time-to-event analyses, Kaplan-Meier curves were used 
to estimate the cumulative probability of the first incident: (i) 
clinical event (AIDS- or non-AIDS-related or death from any 
cause, whichever occurred first); (ii) AIDS-related event or 
AIDS-related death; (iii) non-AIDS-related event or non-AIDS-
related death after 4DR evidence. In these analyses, follow-up 
started at baseline and ended at the date of first event, date of 
death, or last available visit (whichever occurred first) and was 
right-censored 96 months after baseline due to the low number 
of cases observed thereafter; there were no competing events.
Time to first clinical event (either AIDS- or non-AIDS-
related) or death from any cause was estimated by use of 
Kaplan-Meier curves.
Multivariable Cox regression models were fitted to determine 
the factors associated with the risk of ≥1 clinical event (either 
AIDS- or non-AIDS-related) or death from any cause; the ef-
fect estimate was reported as the adjusted hazard ratio (aHR) 
with corresponding 95% CI, estimated according to Wald ap-
proximation. The multivariable model included covariates 
with a P value <.2 on univariable analysis. To define the final 
multivariable model, we fitted different models and assessed 
for collinearity. The multivariable models included the correl-
ated variables, first individually and then in combination; the 
additional contribution of each covariate was assessed with the 
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Akaike information criterion. The variables included in the 
models were fitted as time-fixed and measured at baseline.
For the analyses, 2-sided P values <.05 were considered sta-
tistically significant. All analyses were performed using SAS, re-
lease 9.4 (SAS Institute, Cary, NC, USA).
RESULTS
Overall, 148 PWH harboring a 4DR virus were evaluated and 
contributed to 680 PYFU. They were predominantly males 
(78%), with a median age (IQR) of 49 (44–53) years; 21% were 
co-infected with hepatitis C virus (HCV) and treated with ART 
for 16.8 (14.0–19.7) years. Thirty-nine percent had experienced 
previous AIDS events, and 21% had previous non-AIDS events, 
mostly a non-AIDS malignancy (16%); at baseline, the RGSS 
score (IQR) was 5.5 (3.75–9.5), 93% of people had plasma HIV-1 
RNA >50 copies/mL with a median (IQR) of 3.49 (2.37–4.48) 
log10 copies/mL, the CD4+ cell count was 346 (169–600) cells/µL, 
and the CD4+/CD8+ ratio was 0.35 (0.20–0.61). The other char-
acteristics of the 148 people considered in this study are provided 
in Table 1.
During a median follow-up (IQR) of 47 (32–84) months after 
the first 4DR evidence, 38 PWH had 62 new events or died from 
any cause (12 deaths from any cause [6 AIDS-related deaths and 
6 non-AIDS-related deaths], 17 primary non-AIDS-defining 
malignancies, 3 primary AIDS-defining malignancies, 15 AIDS 
events, 6 MACE, 6 CKD, and 3 cirrhosis).
The incidence rate of any new event or death from any cause 
was 9.12/100 PYFU (95% CI, 6.85–11.39). Fifteen PWH de-
veloped 24 new AIDS events or had AIDS-related death (IR, 
3.52/100 PYFU; 95% CI, 2.12–4.94); the incidence rate of 
AIDS-related events was 2.65/100 PYFU (95% CI, 1.57–4.01). 
Twenty-six PWH developed 38 non-AIDS events or died a non-
AIDS-related death (IR, 5.59/100 PYFU; 95% CI, 3.81–7.37); 
the incidence rate of non-AIDS-related events was 4.71/100 
PYFU (95% CI, 3.08–6.34).
Interestingly, 20 (32% in 16 PWH) of the incident clinical events 
were malignancies, and among the incident non-AIDS events, 
17 (45%) were non-AIDS-defining malignancies. Among the 38 
people who had a first primary malignancy (22 before, 14 after, 
and 2 both before and after the date of 4DR evidence), 1 (3%) in-
dividual had a relapse of the same malignancy (primary diagnosis 
of hepatocellular carcinoma in 2016 with relapse in 2018) and 4 
(11%) individuals had a second diagnosis of cancer: 1 anal cancer 
in 2013 (before 4DR date) followed by cutaneous Kaposi sarcoma 
(KS) in 2019; 1 cutaneous KS in 1997 (before 4DR date) followed 
by squamous cell skin cancer in 2016; 1 Hodgkin lymphoma in 
2010 followed by non-Hodgkin lymphoma in 2017; 1 Hodgkin 
lymphoma in 2014 followed by lung cancer in 2017. At the time 
of this study, 4/38 (11%) had died.
Table 1.  Baselinea Characteristics of the 148 PWH and 4-Class Drug-
Resistant Virus
Baseline Characteristics
Median (IQR) or 
Frequency (%)
Age, y 49 (44–53)
Male gender 115 (78)
HCVAb positive 31 (21)
HBsAg positive 13 (9)
Years from HIV diagnosis 20.4 (16.2–24.5)
Years of ART 16.8 (14.0–19.7)
Pre-ART plasma HIV-RNA, log10 copies/mL 5.18 (4.95–5.67)
Nadir CD4+ cell count, cells/µL 92 (18–203)
Previous AIDS events 58 (39)
Previous non-AIDS events 31 (21)
 Diabetes 9 (6)
 Decompensated cirrhosis 1 (1)
 Malignancies 24 (16)
 MACE 4 (3)
 CKD, eGFR <60 mL/min/1.73 m2 3 (2)
Number of available genotypic resistance tests per 
individual 
3 (2–6)
Residual genotypic susceptibility score, RGSS scoreb 5.5 (3.75–9.5)
 NRTI RGSS 0.5 (0–2)
 NNRTI RGSS 1 (0.5–2.5)
 PI RGSS 1 (0–4)
 INSTI RGSS 1 (0.5–2)
Previous exposure to maraviroc 50 (34)
Previous exposure to enfurvitide 56 (38)
Most frequent ART regimens  
 DRV/b+DTG 21 (14.2)
 DRV/b+DTG+MVC 9 (6.1)
 DRV/b+DTG+ETV 8 (5.4)
 FTC/TAF+DRV/b+DTG 8 (5.4)
 3TC+DRV/b+DTG 6 (4.1)
 DRV/b+DTG+RPV 5 (3.4)
INSTI-including regimen 128 (86.5)
Plasma HIV-1 RNA ≥50 copies/mL 137 (93)
Plasma HIV-RNA, log10 copies/mL 3.49 (2.37–4.48)
CD4+ cell count, cells/µL 346 (169–600)
CD8+ cell count, cells/µL 946 (629–1284)
CD4+/CD8+ ratio 0.35 (0.20–0.61)
Abbreviations: 4DR, 4-class drug-resistant; ART, antiretroviral therapy; chronic CKD, kidney 
disease; eGFR, estimated glomerular filtration rate; INSTI, integrase strand transfer in-
hibitor; MACE, major adverse cardiovascular event; NNRTI, non-nucleoside reverse tran-
scriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; 
RGSS, Residual Genotypic Susceptibility Score.
aBaseline is defined as the date with the first evidence of a 4DR virus.
bThe RGSS was estimated according to the cumulative data of the available plasma 
genotyping resistance tests recorded for each patient until baseline. Based on the patient’s 
cumulative resistance mutations, the level of resistance of each of 24 antiretroviral 
drugs (excluding maraviroc, enfuvirtide) was calculated using the Genotypic Resistance 
Interpretation Algorithm of the Stanford HIV Drug Resistance Database Program (version 
8.8, last updated on 2019-02-13; http://hivdb.stanford.edu). For each of the 24 Food and 
Drug Administration–approved antiretroviral drugs, a drug penalty score was assigned ac-
cording to the degree of resistance. Antiretroviral drug resistance was scored as 1 point 
if classified as “susceptible” or “potential low-level or low-level resistance,” as 0.5 points 
if classified as “intermediate resistance,” and as 0 points if classified as “high-level re-
sistance.” In people with a documented virological failure to an INSTI regimen (n = 21; 11 
individuals failed raltegravir, 8 dolutegravir, and 2 elvitegravir), antiretroviral drug resistance 
(of the failed drug) was scored as 0.5 points; similarly, people previously failing maraviroc-
containing (n = 50) or enfuvirtide-containing (n = 56) regimens were labeled resistant to 
these agents and scored as 0.5 points.
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Kaplan-Meier analysis showed that the estimated probabil-
ities of a clinical event (AIDS event or non-AIDS event or death 
from any cause, whichever occurred first) were 10% (95% CI, 
6%–16%), 13% (95% CI, 9%–20%), 17% (95% CI, 11%–24%), 
and 22% (95% CI, 16%–31%) at 12, 24, 36, and 48 months since 
BL, respectively. People with incident clinical events or death 
from any cause, compared with those without events/death, 
had lower baseline CD4+ cell counts (IQR) (210 [49–443] vs 
436 [223–629] cells/µL; P = .003), lower baseline CD4+/CD8+ 
ratios (IQR) (0.20 [0.09–0.44] vs 0.45 [0.24–0.69]; P = .002), and 
RGSS scores (IQR) that were marginally lower (4.8 [2.5–7.5] vs 
6 [4–10]; P = .072). Baseline HIV-1 RNA was >50 copies/mL in 
95% of people with incident clinical events/death and in 92% of 
people without events/death (P = .792).
Overall, the incidence rate of death from any cause was 
1.76/100 PYFU (95% CI, 0.91–2.90). The cumulative probabil-
ities of death were 1.4% (95% CI, 0.4%–5.6%), 2.2% (95% CI, 
0.7%–6.7%), 3.0% (95% CI, 1.1%–7.9%), and 6.2% (95% CI, 
3.0%–12.8%) at 12, 24, 36, and 48 months since BL, respectively 
(Figure 1).
Twelve months after baseline, 4% (95% CI, 2%–9%) of PWH 
were estimated to have developed an AIDS event or died an 
AIDS-related death, increasing to 6% (95% CI, 3%–11%), 7% 
(95% CI, 4%–12%), and 9% (95% CI, 5%–15%) at 24, 36, and 
48 months, respectively (Figure 1). People with incident AIDS 
events/death, compared with people without AIDS events/
death, had a similar baseline virological profile (HIV-1 RNA >50 
copies/mL: 100% vs 92%; P = .604) and a poor immunological 
profile (CD4+ cell count [IQR], 55 [20–328] vs 416 [204–629] 
cells/µL; P = .0001; CD4+/CD8+ ratio [IQR], 0.10 [0.06–0.24] 
vs 0.38 [0.22–0.69]; P = .0006). At the event’s occurrence or last 
available visit, HIV-1 RNA >50 copies/mL was recorded in 70% 
of people with incident AIDS events/death vs 24% of people 
without AIDS events/death (P = .004), and a poor immunolog-
ical profile was significantly associated with the occurrence of 
incident AIDS events or AIDS-related death (Figure 2).
The estimated probabilities of non-AIDS events or non-
AIDS-related deaths were 5% (95% CI, 3%–10%), 8% (95% 
CI, 5%–15%), 12% (95% CI, 7%–19%), and 15% (95% CI, 
10%–24%) at 12, 24, 36, and 48 months since BL, respectively 
(Figure 2). People with incident non-AIDS events/death, com-
pared with people without non-AIDS events/death, had a sim-
ilar baseline virological profile (HIV-1 RNA >50 copies/mL: 
92% vs 93%; P =  .994) and immunological profile (CD4+ cell 
count [IQR], 282 [168–501] vs 354 [170–601] cells/µL; P = .417; 
CD4+/CD8+ ratio [IQR], 0.26 [0.15–0.54] vs 0.37 [0.21–0.61]; 
P = .266). On the contrary, at the event’s occurrence or last avail-
able visit, people with incident non-AIDS events or non-AIDS-
related death more frequently had HIV-1 RNA >50 copies/mL 
(59% of people with events vs 24% of people without events; 
P = .002) and a poor immunological profile (Figure 3).
The estimated probabilities of any clinical event (AIDS event 
or non-AIDS event) or death from any cause, AIDS event or 
AIDS-related death, non-AIDS events or non-AIDS-related 
deaths, according to according to age (<50 vs ≥50 years), base-










































Follow-up from BL, mo
0 12 24 36 48 60 72 84 96
148 133 123 103 74 59 47 37 22
Figure 1.  Time to death from any cause. Twelve people with HIV died (incidence rate, 1.76/100 person-years of follow-up; 95% CI, 0.91–2.90): 6 AIDS-related deaths 
(1 wasting syndrome, 1 non-Hodgkin lymphoma [Burkitt], 1 tuberculous meningoencephalitis, 1 Pneumocystis jirovecii¸ 1 mycobacteriosis, 1 extrapulmonary Mycobacterium 
tuberculosis) and 6 non-AIDS-related deaths (2 major adverse cardiovascular events, 1 Hodgkin lymphoma, 1 bacterial pneumonia, 1 suicide, 1 unspecified non-AIDS event). 
Abbreviation: BL, baseline.
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load (<50 vs ≥50 copies/mL and ≤200 vs >200 copies/mL) are 
reported in Supplementary Figures 1–12). Age was associated 
only with the occurrence of non-AIDS-related events or non-
AIDS-related death, while baseline CD4+ cell count influenced 
either the burden of disease or the occurrence of AIDS-related 
events or AIDS-related death; viral load stratified on the basis 





























































Follow-up from BL, mo
0 12 24 36 48 60 72 84 96
148 131 120 100 70 57 47 35 21
Figure 2.  Time to occurrence of new AIDS-related events or AIDS-related death. Fifteen people with HIV developed 24 new AIDS events or died an AIDS-related death 
(incidence rate, 3.52/100 person-years of follow-up; 95% CI, 2.12–4.94): 3 atypical mycobacteriosis, 3 pulmonary tuberculosis, 1 tuberculous meningoencephalitis, 2 non-
Hodgkin lymphoma, 1 cutaneous Kaposi sarcoma, 2 esophageal candidiasis, 2 Pneumocystis jirovecii pneumonia, 1 disseminated herpes simplex, 1 wasting syndrome, 1 
































































Follow-up from BL, mo
0 12 24 36 48 60 72 84 96
147 125 112 90 64 54 40 30 19
Figure 3.  Time to occurrence of new non-AIDS-related events or non-AIDS-related death. Twenty-six people with HIV developed 38 non-AIDS events or died a non-AIDS 
related death (incidence rate, 5.59/100 person-years of follow-up; 95% CI, 3.81–7.37): 3 Hodgkin lymphoma, 4 anal cancer, 3 hepatocellular carcinoma, 2 prostate cancer, 1 
lung cancer, 1 breast cancer, 1 laryngeal cancer, 1 conjunctival spinocellular carcinoma, 1 squamous cell skin cancer, 6 major adverse cardiovascular events, 6 chronic kidney 
disease, 3 cirrhosis, and 6 non-AIDS-related deaths. Abbreviation: BL, baseline.
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At multivariate analysis (Table 2), the occurrence of previous 
clinical events (AIDS or non-AIDS) before baseline was asso-
ciated with an increased risk of incident clinical events/death 
(aHR [≥1 vs none], 2.674; 95% CI, 1.067–6.667; P = .036), while 
higher values of BL CD4+/CD8+ ratio were marginally associ-
ated with a lower risk of incident clinical events/death from any 
cause (aHR [per 0.1-unit higher], 0.816; 95% CI, 0.654–1.019; 
P = .072).
DISCUSSION
In this analysis, we reported that a substantial proportion of the 
148 HIV-1 adults with 4DR had new clinical events or death fol-
lowing 4DR evidence, mainly non-AIDS-related (61%); 32% of 
the recorded clinical events were malignancies, and among the 
non-AIDS events, 45% were non-AIDS-defining malignancies. 
The occurrence of new clinical events or death from any cause 
was affected by the immunological profile at 4DR and margin-
ally by a history of clinical events.
While the implication of multidrug resistance on clinical pro-
gression has been previously studied in people with TCVF [5, 
6, 8, 9], no data have been yet reported in HIV-infected people 
with 4DR. Data from the PLATO II project [6], including 91 
764 individuals, showed that the crude incidence of AIDS-
defining events was 1.2/100 PYFU in 2009, and the crude rate 
of death in 2008 was 1.4/100 PYFU. These rates were derived 
around 10 years earlier than our study, when treatment options 
were less effective. However, the rates of AIDS-related events 
and death in our 4DR cohort are definitely higher (2.65 and 
1.76/100-PYFU, respectively). Although the estimates obtained 
from the PRESTIGIO Registry derive from a smaller sample 
size, our findings highlight an excess of clinical events and mor-
tality among PWH and 4DR virus, despite the availability of 
modern and highly effective antiretroviral drugs.
Another relevant finding from our study is the high inci-
dence of non-AIDS events or non-AIDS-related death, with a 
rate much higher than that of the AIDS-related events. Similar 
findings were previously observed in a study of 12 844 PWH by 
Mocroft et al. [10] reporting that non-AIDS events are common 
among PWH in the highly active antiretroviral therapy era, that 
they are associated with considerable mortality, and that there 
is no relationship between the incidence of these events and 
CD4+ levels, especially CD4+ levels >350 cells/µL; the authors 
also observed that the incidence of non-AIDS events was sim-
ilar to, or exceeded, the incidence of AIDS events at CD4 counts 
≥200 cells/µL. We indeed estimated a higher incidence rate of 
non-AIDS events in our study, likely reflecting the higher de-
gree of fragility of people with 4DR compared with the PWH 
population in general.
In our study, one-third of these events were malignancies 
(45% among the incident non-AIDS events), at least in part 
virus-related cancers (Epstein-Barr virus–related, human pap-
illomavirus–related, and HCV-related) followed by cardiovas-
cular events, and we found that the occurrence of these events 
or death is more likely in people with a history of previous 
Table 2.  Univariable and Multivariable Hazard Ratios for Incident Clinical Events or Death From Any Cause Among the 148 PWH and 4-Class Drug-
Resistant Virus
Covariate Category
Univariable Analysis Multivariable Analysisa
Hazard Ratio (95% CI) P Value Adjusted Hazard Ratio (95% CI) P Value
Age Per 1 y older 1.036 (0.993–1.080) .102 1.022 (0.972–1.073) .397
Gender Female vs male 0.546 (0.210–1.418) .194 0.773 (0.264–2.262) .639
HCVAb Positive vs negative 1.227 (0.546–2.758) .621 Not included -
HBsAg Positive vs negative 2.856 (0.377–21.634) .310 Not included -
Years since HIV diagnosis Per 1 y longer 1.003 (0.906–1.024) .230 Not included -
Years of ART Per 1 y longer 0.967 (0.898–1.041) .369 Not included -
Pre-ART HIV-RNA Per 1 log10 copies/mL higher 0.628 (0.181–2.178) .464 Not included -
Nadir CD4+ cell count Per 100 cells/µL higher 0.531 (0.346–0.816) .004 0.756 (0.487–1.173) .212
Previous AIDS events ≥1 vs none 2.313 (1.141–4.688) .020 Not included -
Previous non-AIDS event ≥1 vs none 2.724 (1.327–5.593) .006 Not included -
Previous AIDS or non-AIDS event ≥1 vs none 3.644 (1.760–7.547) 0.0005 2.674 (1.067–6.667) .036
BL plasma HIV-1 RNA ≥50 vs <50 copies/mL 2.209 (0.300–16.250) .436 Not included -
BL plasma HIV-1 RNA Per 1 log10 copies/mL higher 1.299 (0.967–1.745) .083 0.992 (0.615–1.600) .973
BL CD4+ cell count Per 100 cells/µL higher 0.802 (0.687–0.936) .005 Not included -
BL CD8+ cell count Per 100 cells/µL higher 1.031 (0.965–1.101) .363 Not included -
BL CD4+/CD8+ ratio Per 0.1 unit higher 0.729 (0.602–0.885) .001 0.816 (0.654–1.019) .072
Burden of resistance (RGSS score) ≤5.5 vs >5.5b 1.630 (0.830–3.204) .176 Not included -
Burden of resistance (RGSS score) Per 1 point higher 0.962 (0.882–1.049) .179 1.051 (0.936–1.180) .400
Abbreviations: 4DR, 4-class drug-resistant; ART, antiretroviral therapy; BL, baseline (date with the first evidence of a 4DR virus); RGSS, Residual Genotypic Susceptibility Score.
aCovariates with univariable P value <.20 were included in the final multivariable model.
bMedian value.
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clinical events (48% of people had ≥1 clinical event before evi-
dence of 4DR). Most of the observed non-AIDS events are sim-
ilar to those experienced by the general population and, at least 
in part, potentially associated with modifiable lifestyle factors, 
such as smoking.
It is also of interest to note that, in our study, among the 24 
people who survived a first primary malignancy, 4 (17%) indi-
viduals had a diagnosis of a second primary cancer. Although 
the limited sample size of our study might have negatively af-
fected the accuracy of this estimate, this proportion slightly ex-
ceeds that estimated in a recent population study by Hessol and 
colleagues [11] showing that 9% of all the identified primary 
cancers among people with HIV were second or later primary 
cancers, a proportion similar to that of the general population 
of people aged 20–64 years (11%) [12]. Tenorio and colleagues 
reported that in people on suppressive ART inflammation and 
coagulation markers are associated with higher risk of non-
AIDS-defining events and mortality [13]. Borges and colleagues 
[14] also found that activated inflammation and coagulation 
pathways are associated with increased cancer risk during HIV 
infection. We may argue that these conditions are even truer for 
people with a 4DR virus, are frequently characterized by per-
sistent viremia (possibly associated with nonadherence), and 
are likely affected by a higher burden of inflammation [15].
Another finding from this study is that low CD4+/CD8+ 
ratio values are marginally associated with a higher risk of new 
clinical events or death. Low CD4+/CD8+ ratio cell counts 
have long been established as a risk factor for the development 
of clinical events and death, either AIDS-related [16] or non-
AIDS-related [17–19]. In consideration of the fact that most of 
the non-AIDS-related events in our study were malignancies, 
the study by Hema et al. [19] is of particular interest; in fact, 
the authors reported that the risk of cancer was twice as high in 
the subset of patients who had a CD4+/CD8+ ratio <0.5, inde-
pendent of CD4+ cell count. This finding is in line with the me-
dian CD4+/CD8+ ratio we observed in people with 4DR virus 
either at baseline or at the event’s occurrence.
There are some limitations to our study that are important 
to highlight. Although clinical records were carefully moni-
tored, we cannot exclude a potential underestimation of clinical 
events, especially of non-AIDS-related events and mortality for 
which a link with the national death registry is not available in 
Italy. Another issue is related to the recent establishment of the 
PRESTIGIO Registry: Recorded people are those who survived 
a previous potentially fatal event, and for this reason, we might 
have underestimated the true incidences of AIDS- and non-
AIDS-related events and death.
The absence of a control group is an additional study lim-
itation that impairs the assessment of whether the estimated 
incidence rates are similar, lower than, or greater than those 
observed in other individuals. Unfortunately, a study that 
evaluated the same outcomes in individuals with similar 
characteristics and without extensive drug resistance is lacking, 
and at this time, any comparator group can only be inadequate. 
Another limitation is the date we considered baseline for these 
analyses: This is the date on which 4-drug resistance was high-
lighted for the first time, evidence that might be late compared 
with the time when this condition actually occurred. Finally, 
predictive factors were estimated on the composite end point 
including AIDS- and non-AIDS-related events and deaths from 
any cause; this analysis allowed us to increase power, although 
the potential risk factors may differ for each single component 
of the composite end point.
In conclusion, among PWH and 4-class drug-resistant virus, 
the occurrence of clinical events and deaths from any cause was 
particularly high and the incidence of new non-AIDS events/
non-AIDS-related death was almost twice that of new AIDS 
events/AIDS-related death, with a worrying incidence of ma-
lignancies. Because of the high burden of disease in PWH with 
4DR virus, close prevention and monitoring interventions are 
highly recommended, especially in people with a history of 
clinical events and a low CD4+/CD8+ ratio. In PWH with 4DR 
virus, efforts to provide access to drugs with new mechanisms 
of action are also urgently needed in order to achieve undetect-
able HIV-RNA load, preserve the immune system, prevent clin-
ical progression, and ultimately improve quality of life.
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